These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 15723448)

  • 1. Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites.
    Clària J; Kent JD; López-Parra M; Escolar G; Ruiz-Del-Arbol L; Ginès P; Jiménez W; Vucelic B; Arroyo V
    Hepatology; 2005 Mar; 41(3):579-87. PubMed ID: 15723448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.
    Schwartz JI; Vandormael K; Malice MP; Kalyani RN; Lasseter KC; Holmes GB; Gertz BJ; Gottesdiener KM; Laurenzi M; Redfern KJ; Brune K
    Clin Pharmacol Ther; 2002 Jul; 72(1):50-61. PubMed ID: 12152004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites.
    López-Parra M; Clària J; Planagumà A; Titos E; Masferrer JL; Woerner BM; Koki AT; Jiménez W; Altuna R; Arroyo V; Rivera F; Rodés J
    Br J Pharmacol; 2002 Feb; 135(4):891-900. PubMed ID: 11861316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake.
    Huledal G; Jonzon B; Malmenäs M; Hedman A; Andersson LI; Odlind B; Brater DC
    Clin Pharmacol Ther; 2005 May; 77(5):437-50. PubMed ID: 15900289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects.
    Rossat J; Maillard M; Nussberger J; Brunner HR; Burnier M
    Clin Pharmacol Ther; 1999 Jul; 66(1):76-84. PubMed ID: 10430112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.
    Angeli P; Volpin R; Piovan D; Bortoluzzi A; Craighero R; Bottaro S; Finucci GF; Casiglia E; Sticca A; De Toni R; Pavan L; Gatta A
    Hepatology; 1998 Oct; 28(4):937-43. PubMed ID: 9755229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular, renal, and neurohumoral responses to single large-volume paracentesis in patients with cirrhosis and diuretic-resistant ascites.
    Peltekian KM; Wong F; Liu PP; Logan AG; Sherman M; Blendis LM
    Am J Gastroenterol; 1997 Mar; 92(3):394-9. PubMed ID: 9068457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies.
    Daniels S; Robbins J; West CR; Nemeth MA
    Clin Ther; 2009 Jun; 31(6):1192-208. PubMed ID: 19695387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal effects of treatment with diuretics, octreotide or both, in non-azotemic cirrhotic patients with ascites.
    Kalambokis G; Economou M; Fotopoulos A; Bokharhii JA; Katsaraki A; Tsianos EV
    Nephrol Dial Transplant; 2005 Aug; 20(8):1623-9. PubMed ID: 15886218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
    Goldstein JL; Cryer B; Amer F; Hunt B
    Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1167-74. PubMed ID: 17916545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF; Hsiao FY; Wen YW; Tsai YW
    Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of painful temporomandibular joints with a cyclooxygenase-2 inhibitor: a randomized placebo-controlled comparison of celecoxib to naproxen.
    Ta LE; Dionne RA
    Pain; 2004 Sep; 111(1-2):13-21. PubMed ID: 15327804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of dietary supplementation with arachidonic acid on platelet and renal function in patients with cirrhosis.
    Pantaleo P; Marra F; Vizzutti F; Spadoni S; Ciabattoni G; Galli C; La Villa G; Gentilini P; Laffi G
    Clin Sci (Lond); 2004 Jan; 106(1):27-34. PubMed ID: 12877651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impairment of renal function during moderate physical exercise in cirrhotic patients with ascites: relationship with the activity of neurohormonal systems.
    Saló J; Guevara M; Fernández-Esparrach G; Bataller R; Ginès A; Jimenez W; Ginès P; Rivera F; Arroyo V; Rodés J
    Hepatology; 1997 Jun; 25(6):1338-42. PubMed ID: 9185749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease.
    Renda G; Tacconelli S; Capone ML; Sacchetta D; Santarelli F; Sciulli MG; Zimarino M; Grana M; D'Amelio E; Zurro M; Price TS; Patrono C; De Caterina R; Patrignani P
    Clin Pharmacol Ther; 2006 Sep; 80(3):264-74. PubMed ID: 16952493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of imidazole-salicylate on renal function and the diuretic action of furosemide in cirrhotic patients with ascites.
    Salerno F; Lorenzano E; Maggi A; Badalamenti S; Minuz P; Degan M; Chinea B; Scotti A
    J Hepatol; 1993 Sep; 19(2):279-84. PubMed ID: 8301062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
    Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of celecoxib and diclofenac on blood pressure, renal function, and vasoactive prostanoids in young and elderly subjects.
    Dilger K; Herrlinger C; Peters J; Seyberth HW; Schweer H; Klotz U
    J Clin Pharmacol; 2002 Sep; 42(9):985-94. PubMed ID: 12211224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The hepatic safety and tolerability of the cyclooxygenase-2 selective NSAID celecoxib: pooled analysis of 41 randomized controlled trials.
    Soni P; Shell B; Cawkwell G; Li C; Ma H
    Curr Med Res Opin; 2009 Aug; 25(8):1841-51. PubMed ID: 19530981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary prostaglandin E2 excretion, sodium retention, and diuretic responsiveness in patients with chronic liver disease.
    Rector WG
    Am J Gastroenterol; 1987 Apr; 82(4):347-51. PubMed ID: 3471082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.